Clinical trial

A Two-arm Clinical Study to Evaluate the Safety and Efficacy of Gelatin Sponge-loaded Apoptotic Vesicle Complex for Alveolar Bone Defect Repair After Mandibular Third Molar Extraction

Name
Mao Xue Li
Description
Distal bone loss of the second molar due to extraction of the third molar is one of the most common pathological conditions that results in tooth loss of second molar. However, regeneration of functional alveolar bone has proved difficult. Therefore, the investigators conduct a two-arm study to evaluate the efficacy and safety of alveolar bone regeneration induced by gelatin sponge-loaded apoptotic vesicle complex in patients with mandibular third molar extraction.
Trial arms
Trial start
2023-08-20
Estimated PCD
2024-10-30
Trial end
2024-12-30
Status
Not yet recruiting
Treatment
Gelatin sponge-loaded apoptotic vesicle complex(Kuaikang®)
The experimental group
Arms:
Gelatin sponge-loaded apoptotic vesicle complex
Other names:
Gelatin sponge (Kuaikang®). Apoptotic vesicles are derived from umbilical cord mesenchymal stem cells
Gelatin sponge only (Kuaikang®)
The positive control group
Arms:
Gelatin sponge only
Other names:
Gelatin sponge (Kuaikang®)
Size
30
Primary endpoint
Bone volume fraction of regenerated bone tissue in the extraction area at 3 months after operation
3 months
Eligibility criteria
Inclusion Criteria: 1. Patients aged 18-45 (including the boundary value) 2. Patients who need to extract the bilateral mandible third molars 3. Patients who voluntarily sign the informed consent form Exclusion Criteria: 1. The adjacent second molars in the patient's oral cavity are affected by pulp injury or insufficient endodontic treatment, or show tooth fracture, or have a degree of motion of 3 degrees 2. The adjacent second molars have metal crowns or large amalgam restorations 3. There is an uncontrollable pathological process in the patient's oral cavity 4. Malnutrition (serum albumin concentration \<2 g/dl) 5. Other systemic, infectious diseases and hereditary diseases, or patients in the acute inflammatory phase and acute exacerbation phase of chronic diseases 6. Patients who are pregnant, lactating, or planning to become pregnant
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 30, 'type': 'ESTIMATED'}}
Updated at
2023-08-02

1 organization

2 products

1 indication